Mobile Lads Corp. (MOBO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 484.28 Thousand USD | -35.92% |
| 2021 | 755.75 Thousand USD | 15.38% |
| 2020 | 654.99 Thousand USD | 6.11% |
| 2019 | 617.28 Thousand USD | 0.0% |
| 2016 | 10.41 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | 485.03 Thousand USD | 0.16% |
| 2023 Q2 | 484.48 Thousand USD | -0.11% |
| 2022 Q3 | 484.28 Thousand USD | -2.45% |
| 2022 FY | 484.28 Thousand USD | -35.92% |
| 2022 Q1 | 514.29 Thousand USD | 0.0% |
| 2022 Q4 | 484.28 Thousand USD | 0.0% |
| 2022 Q2 | 496.44 Thousand USD | -3.47% |
| 2021 FY | 755.75 Thousand USD | 15.38% |
| 2020 FY | 654.99 Thousand USD | 6.11% |
| 2019 FY | 617.28 Thousand USD | 0.0% |
| 2017 Q1 | 8613.00 USD | -17.33% |
| 2016 Q3 | 154.57 Thousand USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | 10.41 Thousand USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | 10.41 Thousand USD | -93.26% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 98.825% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 88.251% |
| SQZ Biotechnologies Company | 27.47 Million USD | 98.237% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 98.883% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 98.373% |
| Mesoblast Limited | 118.7 Million USD | 99.592% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 48.93% |
| Genus plc | 233.1 Million USD | 99.792% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 83.474% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 63.956% |
| Marizyme, Inc. | 18.71 Million USD | 97.413% |
| ContraFect Corporation | 2.88 Million USD | 83.19% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 35.429% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -257.439% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 66.516% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 79.179% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 91.441% |
| MultiCell Technologies, Inc. | 202.58 USD | -238958.15% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.158% |
| EV Biologics, Inc. | 1.49 Million USD | 67.601% |
| Q BioMed Inc. | 4.1 Million USD | 88.217% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 98.537% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 23.139% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 60.575% |
| Biomind Labs Inc. | 735.54 Thousand USD | 34.16% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.718% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 96.274% |
| Skye Bioscience, Inc. | 4.61 Million USD | 89.507% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 45.467% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -242.207% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 91.751% |
| IMV Inc. | 28.88 Million USD | 98.323% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -1782.981% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 78.556% |
| GB Sciences, Inc. | 1.75 Million USD | 72.473% |
| Alpha Cognition Inc. | 1.22 Million USD | 60.317% |
| HST Global, Inc. | 98.31 Thousand USD | -392.564% |
| CSL Limited | 12.18 Billion USD | 99.996% |
| Halberd Corporation | 150 Thousand USD | -222.856% |
| Enzolytics Inc. | 996.33 Thousand USD | 51.394% |
| Resverlogix Corp. | 6.49 Million USD | 92.539% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -1.421% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -89.475% |
| argenx SE | 20 Million USD | 97.579% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 98.937% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 82.121% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -4636.274% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.884% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -141.398% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 79.802% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -111.209% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.284% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 83.997% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -34.632% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 97.618% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -225.779% |
| BioStem Technologies, Inc. | 4.71 Million USD | 89.721% |
| ONE Bio Corp. | 19.71 Million USD | 97.544% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -93.573% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -94.711% |
| Agentix Corp. | 50 Thousand USD | -868.568% |
| LadRx Corporation | 33.6 Thousand USD | -1341.064% |
| Cell Source, Inc. | 9.25 Million USD | 94.767% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 35.959% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 35.959% |
| NovAccess Global Inc. | 2.19 Million USD | 77.986% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 93.153% |
| Itoco Inc. | 228.37 Thousand USD | -112.055% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -129.546% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 90.281% |
| Kadimastem Ltd | 891.22 Thousand USD | 45.661% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -20.514% |
| CytoDyn Inc. | 30.07 Million USD | 98.39% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -37.641% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 93.807% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -295.334% |
| Rebus Holdings, Inc. | 310 Thousand USD | -56.221% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 89.773% |
| International Stem Cell Corporation | 4.17 Million USD | 88.409% |
| Bioxytran, Inc. | 1.92 Million USD | 74.842% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -675.935% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 77.794% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 94.176% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 94.359% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 68.866% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -80.703% |
| Neutra Corp. | 54.15 Thousand USD | -794.239% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 73.536% |
| PureTech Health plc | 25.51 Million USD | 98.102% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 60.442% |
| IXICO plc | 472.02 Thousand USD | -2.598% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 96.876% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.222% |
| CSL Limited | 12.18 Billion USD | 99.996% |
| Cellectis S.A. | 92.77 Million USD | 99.478% |